SFX-01 – pharmaceutical daily

June 24, 2019 Off

Evgen’s SFX-01 candidate as a new therapeutic for patients after SAH

Evgen Pharma’s lead product, SFX-01, has been featured in a recently published paper, in the journal “Oxidative Medicine and Cellular Longevity”, describing Phase IIb trial in subarachnoid haemorrhage (“SAH”) at University Hospital Southampton.

March 5, 2018 Off

Evgen Pharma remains focused on clinical development of SFX-01, commit to explore therapeutic potential of novel sulforaphane analogues

By Dino Mustafić

The results of an evaluation of Evgen Pharma’s novel sulforaphane analogues suggest that some of the analogues merit further study as…

October 4, 2017 Off

Evgen Pharma gets first European manufacturing patent

By Dino Mustafić

Evgen Pharma got the grant of the first European patent for its lead product, SFX-01.

January 11, 2017 Off

Evgen Pharma gets positive DSMB review of SAS trial

By Dino Mustafić

Evgen Pharma’s anti-stress drug SFX-01, which is currently in its Phase II study has shown good results and it can proceed as planned.